While chemotherapy has a role in the treatment of HR+ breast cancer, there is compelling evidence that it is less effective in HR+ tumors than in hormone receptor negative (HR−) tumors, making treatment decisions about the use of chemotherapy complex. Here, NR4A1 is linked to breast carcinoma.